Atypical Parkinsonism
18
4
8
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 18 trials
100.0%
+13.4% vs benchmark
6%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (18)
Autologous Bone Marrow Aspirate (IV) and Bone Marrow Concentrate (Intranasal) for Parkinson's Disease and Parkinson-Plus Syndromes (SPARC-PD)
Trial of Parkinson's And Zoledronic Acid
Biomarkers in Parkinsonian Syndromes
Prospective Multicenter Registry Study of Multiple System Atrophy in China
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements
AMX0035 and Progressive Supranuclear Palsy
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)
Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism
Proteinopathies Expression in Skin of Neurodegenerative Disorders
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism.
Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkinsonism
Utilizing Smart Devices to Identify New Phenotypical Characteristics in Movement Disorders
Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism
Spinal Cord Stimulation for Gait in Parkinson Disease
Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans
Parkinson's Disease, Diagnostic Observations (PADDO)